March 16, 2021


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



Ms. Tara Harkins

Ms. Kate Tillan

Ms. Margaret Schwartz

Ms. Laura Crotty



Finch Therapeutics Group, Inc.

Registration Statement on Form S-1

File No. 333-253622

Acceleration Request

Requested Date: March 18, 2021

Requested Time: 4:00 PM, Eastern Daylight Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters, hereby join Finch Therapeutics Group, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-253622) (the “Registration Statement”) to become effective on March 18, 2021, at 4:00 PM, Eastern Daylight Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]

Very truly yours,
BofA Securities Inc.

/s/ Aamir Mecklai

Name:   Aamir Mecklai
Title:   Managing Director
Jefferies LLC

/s/ Matthew Kim

Name:   Matthew Kim
Title:   Joint US Head of Biopharmaceuticals
Evercore Group L.L.C.

/s/ Edmund Baxter

Name:   Edmund Baxter
Title:   Senior Managing Director



Joseph D. Vittiglio, Finch Therapeutics Group, Inc.

Edwin M. O’Connor, Goodwin Procter LLP

Seo Salimi, Goodwin Procter LLP

Ryan S. Sansom, Cooley LLP

Courtney T. Thorne, Cooley LLP

[Signature Page to Acceleration Request]